tiprankstipranks
Advertisement
Advertisement

HK:2616 Stock Latest News

CStone’s 2025 Loss Widens as R&D Spend Climbs Ahead of Pralsetinib NRDL Boost
Company AnnouncementsCStone’s 2025 Loss Widens as R&D Spend Climbs Ahead of Pralsetinib NRDL Boost
12d ago
2616
CStone Fast-Tracks Global Phase III Plan After Strong Early Data for Trispecific Cancer Antibody CS2009
PremiumCompany Announcements
CStone Fast-Tracks Global Phase III Plan After Strong Early Data for Trispecific Cancer Antibody CS2009
12d ago
2616
CStone’s Sugemalimab Wins Top ESMO Backing for Stage III Lung Cancer
PremiumCompany Announcements
CStone’s Sugemalimab Wins Top ESMO Backing for Stage III Lung Cancer
13d ago
2616
CStone to Showcase Three ADC Pipeline Programs at 2026 AACR Meeting
PremiumCompany Announcements
CStone to Showcase Three ADC Pipeline Programs at 2026 AACR Meeting
20d ago
2616
CStone Wins Second UK Approval for Lung Cancer Drug Sugemalimab
PremiumCompany Announcements
CStone Wins Second UK Approval for Lung Cancer Drug Sugemalimab
1M ago
2616
CStone Wins U.S. FDA Green Light for Phase II Trial of Trispecific Cancer Antibody CS2009
PremiumCompany AnnouncementsCStone Wins U.S. FDA Green Light for Phase II Trial of Trispecific Cancer Antibody CS2009
2M ago
2616
CStone Pharmaceuticals Streamlines Company Secretary and Authorized Representative Roles
Premium
Company Announcements
CStone Pharmaceuticals Streamlines Company Secretary and Authorized Representative Roles
2M ago
2616
CStone Pharmaceuticals Sets March Board Meeting and Investor Call to Detail 2025 Results and Oncology Pipeline Progress
Premium
Company Announcements
CStone Pharmaceuticals Sets March Board Meeting and Investor Call to Detail 2025 Results and Oncology Pipeline Progress
2M ago
2616
CStone CEO Boosts Stake to 4.87% in Sign of Long-Term Confidence
PremiumCompany Announcements
CStone CEO Boosts Stake to 4.87% in Sign of Long-Term Confidence
2M ago
2616
CStone Pharmaceuticals Grants New Share Options and RSUs, Seeks Shareholder Nod for Director Awards
PremiumCompany Announcements
CStone Pharmaceuticals Grants New Share Options and RSUs, Seeks Shareholder Nod for Director Awards
2M ago
2616
CStone Pharmaceuticals Reshapes Board With New Independent Director Appointment
PremiumCompany Announcements
CStone Pharmaceuticals Reshapes Board With New Independent Director Appointment
3M ago
2616
CStone Pharmaceuticals Sets Out Board and Committee Structure
PremiumCompany Announcements
CStone Pharmaceuticals Sets Out Board and Committee Structure
3M ago
2616
CStone Pharmaceuticals’ GAVRETO® Gains Inclusion in China’s National Reimbursement Drug List
PremiumCompany AnnouncementsCStone Pharmaceuticals’ GAVRETO® Gains Inclusion in China’s National Reimbursement Drug List
4M ago
2616
CStone’s Sugemalimab Gains European Approval for Broader NSCLC Treatment
Premium
Company Announcements
CStone’s Sugemalimab Gains European Approval for Broader NSCLC Treatment
4M ago
2616
CStone Pharmaceuticals Unveils CS2015 at ACAAI 2025
Premium
Company Announcements
CStone Pharmaceuticals Unveils CS2015 at ACAAI 2025
5M ago
2616
CStone Pharmaceuticals Advances CS2009 Clinical Trials with NMPA Approval
PremiumCompany Announcements
CStone Pharmaceuticals Advances CS2009 Clinical Trials with NMPA Approval
5M ago
2616
CStone Pharmaceuticals Announces Board Composition and Roles
PremiumCompany Announcements
CStone Pharmaceuticals Announces Board Composition and Roles
5M ago
2616
CStone Pharmaceuticals Announces Board Changes with New Appointment
PremiumCompany Announcements
CStone Pharmaceuticals Announces Board Changes with New Appointment
5M ago
2616
CStone Pharmaceuticals CEO Increases Shareholding, Signaling Confidence in Future Growth
PremiumCompany Announcements
CStone Pharmaceuticals CEO Increases Shareholding, Signaling Confidence in Future Growth
6M ago
2616
CStone Pharmaceuticals Unveils Promising Phase I Data for Innovative Cancer Therapy
PremiumCompany AnnouncementsCStone Pharmaceuticals Unveils Promising Phase I Data for Innovative Cancer Therapy
6M ago
2616
CStone Pharmaceuticals Gains CHMP Positive Opinion for Sugemalimab in Stage III NSCLC
Premium
Company Announcements
CStone Pharmaceuticals Gains CHMP Positive Opinion for Sugemalimab in Stage III NSCLC
6M ago
2616
CStone Pharmaceuticals to Present Groundbreaking Clinical Data at ESMO 2025
Premium
Company Announcements
CStone Pharmaceuticals to Present Groundbreaking Clinical Data at ESMO 2025
6M ago
2616

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >